First Time Loading...

Johnson & Johnson

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
Price: 155.75 USD -0.72% Market Closed
Updated: Sep 30, 2023

Intrinsic Value

Intrinsic Value History
Johnson & Johnson

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Johnson & Johnson's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis


Balance Sheet Decomposition
Johnson & Johnson

Current Assets 60.6B
Cash & Short-Term Investments 28.5B
Receivables 16.8B
Other Current Assets 15.3B
Non-Current Assets 131B
Long-Term Investments 493m
PP&E 20.6B
Intangibles 91.7B
Other Non-Current Assets 18.4B
Current Liabilities 54.2B
Accounts Payable 10.4B
Accrued Liabilities 29.3B
Short-Term Debt 9.8B
Other Current Liabilities 4.6B
Non-Current Liabilities 62.4B
Long-Term Debt 33.9B
Other Non-Current Liabilities 28.5B
Fundamental Scores

JNJ Profitability Score
Profitability Due Diligence

Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Year Average ROE
Positive Operating Income

Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

JNJ Solvency Score
Solvency Due Diligence

Johnson & Johnson's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Positive Net Debt

Johnson & Johnson's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

JNJ Price Targets Summary
Johnson & Johnson

Wall Street analysts forecast JNJ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JNJ is 187.29 USD with a low forecast of 168.67 USD and a high forecast of 225.75 USD.

Price Target
168.67 USD
8% Upside
Price Target
187.29 USD
20% Upside
Price Target
225.75 USD
45% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape


JNJ Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

JNJ Return Decomposition
Main factors of price return

What is price return decomposition?

JNJ Price
Johnson & Johnson

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 8.01%
Standard Deviation of Annual Returns 11.08%
Max Drawdown -27%
Shares Statistics
Market Capitalization 405B USD
Shares Outstanding 2 598 730 000
Percentage of Shares Shorted 1.37%

JNJ News

Last Video News
Johnson & Johnson

Other Videos

Last Important Events
Johnson & Johnson

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.


Sentiment Analysis
Johnson & Johnson

Last 7 Days
Last 30 Days
Last 90 Days

Company Profile

Johnson & Johnson Logo
Johnson & Johnson


United States of America



Market Cap

405B USD

Dividend Yield



Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 141,700 full-time employees. The firm operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.


New Brunswick
One Johnson & Johnson Plaza




141 700


Exec. Chairman
Mr. Alex Gorsky
CEO & Director
Mr. Joaquin Duato
Exec. VP & CFO
Mr. Joseph J. Wolk CPA
Exec. VP & Worldwide Chairman of Pharmaceuticals
Ms. Jennifer L. Taubert
Controller & Chief Accounting Officer
Mr. Robert J. Decker Jr.
Exec. VP & Chief Information Officer
Mr. James Swanson
Show More
VP of Investor Relations
Ms. Jessica Moore
Chief Compliance Officer
Mr. Dirk Brinckman
Exec. VP & Gen. Counsel
Ms. Elizabeth Forminard
Exec. VP & Chief HR Officer
Dr. Peter M. Fasolo Ph.D.
Show Less

See Also

Other Stocks
What is the Intrinsic Value of one JNJ stock?

The intrinsic value of one JNJ stock under the Base Case scenario is 139.51 USD.

Is JNJ stock undervalued or overvalued?

Compared to the current market price of 155.75 USD, Johnson & Johnson is Overvalued by 10%.